
    
      This phase II study was designed to evaluate the efficacy and safety of albumin-bounded
      paclitaxel combined with S-1 as first-line chemotherapy for inoperable and /or metastatic
      gastric or gastroesophageal junction cancer.Primary endpoint was overall response rate.
    
  